What's New
Protected: AFTD and Alector Discuss FTD Research
There is no excerpt because this is a protected post.
Pave the Path Forward to End FTD with a Year-End Gift
Since AFTD was founded in 2002 by Helen-Ann Comstock with her personal gift of $1,000, our work has been powered by the dedication of volunteers, donors, and all those we…
Alector Therapeutics Announces Results From Their Phase 3 Clinical Trial Evaluating Latozinemab
On October 21, 2025, Alector Therapeutics announced results from their Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) for people with FTD caused by variants in the progranulin (GRN gene).…
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic
KING OF PRUSSIA, Pa., Oct. 21, 2025 — Biotechnology company Alector announced today that the drug, latozinemab, failed to meet the criteria for safety and efficacy in a Phase 3…
AFTD Webinar: Talking to Family About Genetic FTD Risk
When a family learns FTD is genetic, it’s important to find relatives and convey the potential risk to them, as well as raise awareness around the hope research progress offers…
New York State FTD Registry Bill Signed into Law
KING OF PRUSSIA, Pa., Oct. 20, 2025 — New York State Governor Kathy Hochul on Friday signed into law a bill creating the nation’s first state-level frontotemporal dementia (FTD) registry. The New…
Advancing Hope: AFTD Convenes 3rd Annual FTD Research Roundtable Meeting
AFTD’s 2025 FTD Research Roundtable, in-person meeting, was held September 15-17 in Arlington, Virginia. Approximately 100 scientific stakeholders from academia, the biopharmaceutical industry, government & regulatory representatives, nonprofit partners, persons…
Epilepsy More Common in FTD than Alzheimer’s, Study Finds
Epilepsy symptoms and the prescription of antiseizure medications are more common in FTD than Alzheimer’s disease, as reported in a study published in JAMA Neurology. The study sheds light on…
AFTD Webinar: The Lived Experience with FTD: The Road to an FTD Diagnosis
While awareness of FTD disorders is increasing, many people still face a lengthy and complicated path to receiving a diagnosis. In this webinar, presenters will share their personal journeys…
Advancing Hope – AFTD Staff Attend 2025 ALS Nexus in Dallas
Amanda Gleixner, PhD, attended the Amyotrophic Lateral Sclerosis (ALS) Nexus, held in Dallas, TX in August. The ALS Nexus is an annual conference hosted by the ALS Association which brings…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)